Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Ge Zou

Wei Zhu

Fabian Dey

Hongtao Xu

Hong Shen

Zongxing Qiu

Hongying Yun

Dongdong Chen

Zhisen Zhang

Dong Ding

The present invention relates to compounds of formula (I), wherein Rto Rand n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease

The present invention relates to compounds of formula (I), wherein Rand Rand n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease

The present invention relates to compounds of formula (I), wherein Rto R, m and n are I a described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease

The present invention relates to compounds of formula (I), wherein Rto Rare as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Piperazine compounds for the treatment of autoimmune disease

The present invention relates to compounds of formula (I), (I), wherein R, Rand Rare as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds. 

Benzothiazole compounds for the treatment of autoimmune diseases

The present invention relates to compounds of formula (I), wherein R, Rand Rare as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds as antagonist of TLR7 and/or TLR8 and/or TLR9 in the treatment of autoimmune diseases as well as auto-inflammation diseases. 

Growing community of inventors

Shanghai, China

Ge Zou